Polycycloalkylpurines useful as adenosine receptor antagonists

摘要

A polycycloalkylpurine derivative has the formula (I) wherein: R1 and R2 are independently hydrogen, or optionally substituted alkyl, alkenyl, alkynyl or aryl; R3 is an optionally substituted bicyclic, tricyclic or pentacyclic group of formula (II); X1 and X2 are independently O or S; Z is a single bond, -O-, -(CH2)1-3-, -O(CH2)1-2-, -CH2OCH2-, -(CH2)1-2O-, -CH=CHCH2-, -CH=CH- or -CH2CH=CH- and R6 is hydrogen, acyl, alkylsulphonyl, optionally substituted aralkyl or alkyl or heterocyclyl The compounds are useful in treating a condition characterized by an elevated adenosine concentration and/or increased sensitivity to adenosine such as cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, diseases for which diuretic treatment is indicated, Parkinson's disease, depression, traumatic brain damage, post-stroke neurological deficit, respiratory depression, neonatal brain trauma, dyslexia, hyperactivity, cystic fibrosis, neonatal apnea, renal failure, diabetes, asthma, or edematous conditions.